Spermatogenic failure Cell Models for Research

Spermatogenic failure is a major cause of male infertility, affecting approximately 7% of men worldwide. According to the World Health Organization (WHO), infertility affects 15% of couples, with male factors contributing to about 50% of cases. Spermatogenic failure encompasses a spectrum of disorders, including non-obstructive azoospermia (NOA), severe oligozoospermia, and Sertoli cell-only syndrome. The prevalence of NOA is estimated at 1% of all men and 10-15% of infertile men. The condition has significant psychological and social impacts, and treatment options are limited, often relying on assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI) with surgically retrieved sperm. However, success rates remain suboptimal, highlighting the need for better understanding and therapeutic interventions. Research into spermatogenic failure is critical for developing novel treatments and improving reproductive outcomes.

Spermatogenic failure is an ideal model for studying fundamental mechanisms of spermatogenesis, including germ cell development, meiosis, and hormonal regulation. The disease is heterogeneous, with both genetic and environmental factors contributing. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas, provide valuable resources for studying testis-specific gene expression. Open questions include the identification of novel genetic causes, the role of epigenetic modifications, and the development of in vitro models for spermatogenesis. Gene-edited cell models, such as CRISPR knockout and knock-in lines, offer powerful tools to dissect the molecular pathways involved and to screen for potential therapeutic targets.

While spermatogenic failure is not a cancer, it shares some molecular pathways with testicular cancer, such as dysregulation of germ cell development. Key pathways involved in spermatogenic failure include:

• • Hormonal signaling: The hypothalamic-pituitary-gonadal axis regulates spermatogenesis. Disruptions in FSH, LH, and testosterone signaling can lead to spermatogenic failure.
• • Apoptosis and autophagy: Imbalances in these processes can lead to germ cell loss.
• • Meiotic recombination: Defects in meiotic genes (e.g., SYCP3, MLH1) can cause meiotic arrest.
• • Sertoli cell function: Sertoli cells support germ cell development; dysfunction can lead to impaired spermatogenesis.

Data from ClinVar, COSMIC, and NCBI Gene.

Key signaling networks involved in spermatogenic failure include:

• • KIT/KITL signaling: Essential for primordial germ cell migration and proliferation.
• • TGF-β/BMP signaling: Regulates Sertoli cell function and germ cell apoptosis.
• • Wnt signaling: Involved in spermatogonial stem cell self-renewal.
• • PI3K/AKT pathway: Promotes germ cell survival.
• • MAPK/ERK pathway: Regulates meiotic progression.

Organoids derived from testicular tissue can recapitulate spermatogenesis in vitro, providing a more physiologically relevant model. They can be used for drug screening and studying cell-cell interactions.

• • Genetically engineered mouse models (GEMMs): Knockout mice for genes like DAZL, SYCP3, and TEX11 exhibit spermatogenic failure.
• • Chemically induced models: Administration of busulfan or radiation can deplete germ cells.
• • Surgical models: Vasectomy or efferent duct ligation can cause obstructive azoospermia.
• • Patient-derived xenografts (PDX): Testicular tissue from patients can be xenografted into immunodeficient mice to study spermatogenesis.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts or knock-ins of disease-associated mutations. For example, a DAZL knockout in a spermatogonial stem cell line can model the effects of DAZL loss on germ cell differentiation. Similarly, a SYCP3 knockout in a spermatocyte cell line can be used to study meiotic defects. These gene-edited cell models are commercially available and sequence-verified, ensuring reproducibility and accelerating research. They are valuable for functional genomics, drug screening, and understanding disease mechanisms.

Gene-edited cell lines allow researchers to validate the function of candidate genes identified in patient cohorts. For example, knocking out TEX11 in a spermatocyte cell line can confirm its role in meiotic recombination. Knock-in of a patient-specific mutation can reveal its impact on protein function. These models are essential for understanding genotype-phenotype correlations.

Isogenic pairs (wild-type vs. knockout) can be used to screen for compounds that rescue or exacerbate the phenotype. For instance, a Sertoli cell line with a knockout of a gene involved in support function can be used to test drugs that enhance spermatogenesis. Resistance mechanisms can also be studied by introducing mutations that confer resistance to chemotherapeutic agents, which is relevant for fertility preservation in cancer patients.

CRISPR-based synthetic lethality screens can identify genes that are essential for survival in the absence of a specific gene, revealing potential therapeutic targets. For example, in a spermatogonial stem cell line with a knockout of a gene critical for self-renewal, a screen can identify genes that, when inhibited, selectively kill the mutant cells, providing a strategy for targeted therapy.